Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Amplitude Ventures
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 10, 2021
LQTT is advancing a series of in- licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1).